Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 563

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 563
---
 next twelve months. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. NOTE 3 — INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 6,000,000Units at a price of $ 10.00per Unit. On February 17, 2023, the underwriters exercised their over -allotmentoption to purchase an additional 900,000Units. Each Unit consists of oneshare of common stock, oneredeemable warrant entitling the holder thereof to purchase oneshare of Common Stock at a price of $ 11.50per share, subject to adjustment, and oneright which entitles the holder thereof to receive one -tenth(1/10) of a share of common stock (see Note 6). Each warrant will become exercisable 30 daysafter the consummation of an initial business combination, and will expire fiveyears after the completion of an initial business combination, or earlier upon redemption or liquidation. Each right entitles the holder thereof to receive one -tenth(1/10) of a share of common stock upon the consummation of an initial business combination, as described in more detail below. Each tenrights entitle the holder thereof to receive one share of common stock at the closing of a business combination. F-15 BELLEVUE LIFE SCIENCES ACQUISITION CORP. NOTES TO CONDENSED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (UNAUDITED) NOTE 4 — RELATED PARTY TRANSACTIONS Founder Shares On July 30, 2020, the Sponsor purchased 1,437,500shares of the Company’s Common Stock (the “Founder Shares”) for an aggregate purchase price of $ 25,000, or approximately $ 0.017per share. On April 25, 2022, the Company executed a 1.2 -for-onestock split, resulting in an aggregate of 1,725,000Founder Shares held by the Company’s sponsor, of which up to 225,000Founder Shares were subject to forfeiture to the extent that the underwriters’ over -allotmentoption was not exercised in full or in part. The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (